摘要:
The present invention relates, in one aspect, to an adduct of formula O-PF-A, in which O is an oil; PF is a perfluoropolyether phosphate (PFPE phosphate); A is at least one substance selected from: (X) a water-soluble polyhydroxylated substance and (Y) a water-insoluble inorganic substance and to topical applications thereof in particular in the cosmetic and pharmaceutical field.
摘要:
According to one aspect, the present invention relates to the use of a perfluoropolyether phosphate (PFPE phosphate), dissolved in water, for the preparation of oil-in-water emuisions (O/W) with high internal phase (HIPE). The internal phase (O) typically comprises at least 74% by volume of the emulsion and includes one or more OiIs1 which acquire, after a treatment with PFPE phosphate, some typical characteristics of high fluorine content compounds, in particular lipophobicity and homophobicity, combined with limited hydrophilicity.
摘要:
The present invention relates, in one aspect, to an adduct of formula O-PF-A, in which O is an oil; PF is a perfluoropolyether phosphate (PFPE phosphate); A is at least one substance selected from: (X) a water-soluble polyhydroxylated substance and (Y) a water-insoluble inorganic substance and to topical applications thereof in particular in the cosmetic and pharmaceutical field.
摘要:
The present invention relates to a system for the release of cosmetic agents comprising at least one phospholipid, hyaluronic acid or derivatives thereof and a cationic polyurethane derivative. The system of the invention may be used in the formulation of cosmetic preparations for obtaining the protracted release of cosmetic agents or active substances to the epidermis or the keratinic structures of the human body, with a simultaneous reduction in the frequency of application.
摘要:
The present invention relates to the use of an agent to combat and reduce the irritating action of primary surfactants in compositions to be applied to the skin for care or cleansing of the face and body, characterized in that said agent is chosen from Cone or more salts of glycyrrhizic acid, such as monoammonium glycyrrhizinate (MAG) and dipotassium glycyrrhizinate (DPG).
摘要:
The object of the invention is a mixture of catechin and quercetin in a molar ratio varying between 3:1 and 6:1, respectively, for the treatment of the immunosuppression induced in the skin by aggressive agents such as airborne pollutants, dehydrating agents, ultraviolet radiation, and thermal and osmotic shocks, and a pharmaceutical, dermatological, nutritional or cosmetic composition containing said mixture as an active ingredient.
摘要:
The object of the present invention is the use of compounds designed to inhibit the activity of the enzyme 5α-reductase. This is a novel use of compounds of general formula (I): CH3(—CH═CH)n—R (I) where n=from 2 to 7, and R is chosen from among: CHO, CH2OH, CH2O—CO—R′, CO—O(−), where R′ is chosen from among H, and the alky from C1 to C22, each compound of general formula (I) being used as such or in mixtures with other compounds, as the active principle in a pharmaceutical or cosmetic composition designed to inhibit the action of the enzyme 5α-reductase, and of the pharmaceutical or cosmetic compositions deriving therefrom.
摘要:
The present invention concerns a mixture of lactic bacteria for yeasting of gluten-free baked products. Particularly, the invention concerns the use of “natural yeast” based on selected lactic bacteria as yeasting agent for the production of gluten-free bread, with improved sensory and nutritional property, designed for celiac patients feeding.
摘要:
This invention regards the use of zeaxanthin and/or rutin, as such or further combined with spermidine, as the active principle in a pharmaceutical, dietary, or cosmetic composition, acting to inhibit caspase-3 and therefore to control apoptosis by preventing programmed cell death.The indication for this composition according to the invention is primarily the treatment of scalp disorders characterized by excessive cellular turnover including chemotherapy-induced alopecia, alopecia areata, androgenetic alopecia and telogen effluvium.
摘要:
The present invention concerns a process for synthesis of 2,4,6-octatriene-1-oic acid and 2,4,6-octatriene-1-ol, which comprises the following stages: a) reaction between 2,4-trans-hexadienal and triethyl phosphonoacetate to give ethyl 2,4,6-trans-octatrienoate; b) alkaline hydrolysis of ethyl 2,4,6-trans-octatrienoate to give the corresponding alkaline salt; c) acidification of said salt to give 2,4,6-trans-octatrienoic acid, which can be separated or can undergo the following further stages: d) reaction of the 2,4,6-trans-octatrienoic acid with ethyl chloroformiate to give the mixed anhydride formed by 2,4,6-trans-octatrienoic acid and ethyl carbonic acid; e) reduction of said mixed anhydride with sodium borohydride to give 2,4,6-trans-octatrienol; and optionally a purification stage of the end product.